HARVARD BIOSCIENCE INC Form SC 13G/A February 10, 2010

> UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

> > SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 1)

Harvard Bioscience, Inc. (Name of Issuer)

Common Stock, \$0.01 par value per share (Title of Class of Securities)

> 416906105 (CUSIP Number)

December 31, 2009 (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- [] Rule 13d-1(b)
- [X] Rule 13d-1(c)
 [] Rule 13d-1(d)

Page 1 of 8 Pages

CUSIP No. 416906105

13G

Page 2 of 8 Pages

^{*}The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

	Highbridge International LLC							
(2)			THE APPROPRIATE BOX IF A MEMBER OF A GROUP istructions)	(a) (b)				
(3)	SEC USE ONLY							
(4)	CIT	IZEN	NSHIP OR PLACE OF ORGANIZATION					
	Cayr	man	Islands, British West Indies					
NUMBER OF		(5)	SOLE VOTING POWER					
SHARES	-		0					
BENEFICIALLY	Y	(6)	SHARED VOTING POWER					
OWNED BY	-		0					
EACH		(7)	SOLE DISPOSITIVE POWER					
REPORTING	-		0					
PERSON WITH		(8)	SHARED DISPOSITIVE POWER 0					
(9)			GATE AMOUNT BENEFICIALLY OWNED CH REPORTING PERSON					
(10)			BOX IF THE AGGREGATE AMOUNT (9) EXCLUDES CERTAIN SHARES (see instructi		[]			
(11)	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9							
(12)	TYI OO	PE C	OF REPORTING PERSON (see instructions)					
CUSIP No. 43	16906	6105	5 13G	Page	3 of	8 Page		
(1)	NAMI	ES C	PF REPORTING PERSONS					
	High	nbri	dge Capital Management, LLC					
(2)			THE APPROPRIATE BOX IF A MEMBER OF A GROUP istructions)	(a) (b)				
(3)	SEC USE ONLY							
(4)	CIT	IZEN	NSHIP OR PLACE OF ORGANIZATION					
	Stat	te d	of Delaware					

NUMBER OF		(5)	SOLE VOTING POWER 0					
SHARES	-							
BENEFICIALLY			SHARED VOTING POWER 0					
OWNED BY	-							
EACH		(7)	SOLE DISPOSITIVE POWER 0					
REPORTING	-							
PERSON WITH			SHARED DISPOSITIVE POWER 0					
(9)			ATE AMOUNT BENEFICIALLY OWNED REPORTING PERSON					
(10)			BOX IF THE AGGREGATE AMOUNT (9) EXCLUDES CERTAIN SHARES (see instructions)		[]			
	0%		OF CLASS REPRESENTED BY AMOUNT IN ROW (9)					
			REPORTING PERSON (see instructions)					
CUSIP No. 41	L6906	5105	13G	Page	4 of	8 Pages		
(1)	NAME	ES OF	REPORTING PERSONS					
	Glenn Dubin							
(2)			HE APPROPRIATE BOX IF A MEMBER OF A GROUP structions)	(a) (b)				
(3)	SEC	USE						
(4)	CITI	ZENS	GHIP OR PLACE OF ORGANIZATION					
	United States							
NUMBER OF		(5)	SOLE VOTING POWER 0					
SHARES	-							
BENEFICIALLY		(6)	SHARED VOTING POWER					
OWNED BY	-							
EACH		(7)	SOLE DISPOSITIVE POWER					

REPORTING		-
PERSON WITH	(8) SHARED DISPOSITIVE POWER 0	_
(9)	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0	
(10)	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)	
(11)	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0%	
(12)	TYPE OF REPORTING PERSON (see instructions) IN	_

CUSIP No. 416906105

13G

Page 5 of 8 Pages

This Amendment No. 1 (this "Amendment") amends the statement on Schedule 13G filed on April 13, 2009 (the "Original Schedule 13G" and the Original Schedule 13G as amended, the "Schedule 13G") with respect to the shares of Common Stock, \$0.01 par value per share (the "Common Stock"), of Harvard Bioscience, Inc., a Delaware corporation (the "Company"). Capitalized terms used herein and not otherwise defined in this Amendment have the meanings set forth in the Schedule 13G. This Amendment amends and restates Items 2(a), 2(b), 2(c), 4 and 5 in their entirety as set forth below.

Item 2(a). Name of Person Filing

Item 2(b). Address of Principal Business Office

Item 2(c). Citizenship

HIGHBRIDGE INTERNATIONAL LLC
c/o Harmonic Fund Services
The Cayman Corporate Centre, 4th Floor
27 Hospital Road
Grand Cayman, Cayman Islands, British West Indies
Citizenship: Cayman Islands, British West Indies

HIGHBRIDGE CAPITAL MANAGEMENT, LLC 40 West 57th Street, 33rd Floor New York, New York 10019 Citizenship: State of Delaware

GLENN DUBIN c/o Highbridge Capital Management, LLC 40 West 57th Street, 33rd Floor New York, New York 10019 Citizenship: United States

Item 4. Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount beneficially owned:

As of December 31, 2009, each of Highbridge International LLC, Highbridge Capital Management, LLC and Glenn Dubin (collectively, the "Reporting Persons") no longer beneficially owned any shares of Common Stock of the Company.

Highbridge Capital Management, LLC is the trading manager of Highbridge International LLC. Glenn Dubin is the Chief Executive Officer of Highbridge Capital Management, LLC. The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of shares of Common Stock owned by another Reporting Person. In addition, each of Highbridge Capital Management, LLC and Glenn Dubin disclaims beneficial ownership of shares of Common Stock owned by Highbridge International LLC.

(b) Percent of class:

0%. See Item 4(a).

CUSIP No. 416906105

13G Page 6 of 8 Pages

- (c) Number of shares as to which such person has:
 - (i) Sole power to vote or to direct the vote

(ii) Shared power to vote or to direct the vote

See Item 4(a)

(iii) Sole power to dispose or to direct the disposition of

0

(iv) Shared power to dispose or to direct the disposition of

See Item 4(a)

Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [X]

Exhibits:

Exhibit I: Joint Filing Agreement, dated as of February 10, 2010, by and among Highbridge International LLC, Highbridge Capital Management, LLC and Glenn

Dubin.

CUSIP No. 416906105

13G

Page 7 of 8 Pages

SIGNATURES

After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

Dated: February 10, 2010

HIGHBRIDGE CAPITAL MANAGEMENT, LLC HIGHBRIDGE INTERNATIONAL LLC

By: Highbridge Capital Management, LLC

its Trading Manager

By: /s/ John Oliva By: /s/ John Oliva

Name: John Oliva Name: John Oliva

Title: Managing Director Title: Managing Director

/s/ Glenn Dubin

GLENN DUBIN

CUSIP No. 416906105

13G

Page 8 of 8 Pages

EXHIBIT I

JOINT FILING AGREEMENT

This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the shares of Common Stock, \$0.01 par value per share, of Harvard Bioscience, Inc., is being filed, and all amendments thereto will be filed, on behalf of each of the persons and entities named below in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

Dated as of February 10, 2010

HIGHBRIDGE CAPITAL MANAGEMENT, LLC HIGHBRIDGE INTERNATIONAL LLC

By: Highbridge Capital Management, LLC

its Trading Manager

By: /s/ John Oliva By: /s/ John Oliva

Name: John Oliva Name: John Oliva

Title: Managing Director Title: Managing Director

/s/ Glenn Dubin
-----GLENN DUBIN